We plan to isolate and characterize the factor(s) through which osteoclasts stimulate osteoclastic resorption by analysis of supernatants using the isolated osteoclast resorption assay. We will identify the responsiveness of osteoclasts to cytokines and growth factors, and other known and potential regulators of bone resorption. The role of second messengers in the regulation of bone resorption by osteoclasts will be assessed, and we will identify those matrix components in bone that mediate adhesion and modulate bone resorption by osteoclasts. The lineage and regulation of differentiation of the osteoclast will be analyzed using the primary function of osteoclasts, the excavation of bone, supported by the osteoclast-specific monoclonal antibodies we have developed, as criteria for osteoclast-differentiation. Osteoclast lineage will be identified in semi-solid cultures of bone marrow cells. The effects of calcium-regulating hormones, cytokines and osteoblastic cells on osteoclastic development in colonies will be assessed. We will attempt to identify circulating precursors of osteoclasts in normal individuals and in patients and laboratory animals with increased levels of osteolysis by immunocytochemistry and the ability to excavate bone slices. We will identify leukemias that consist entirely or partially of osteoclastic precursors, using both fresh peripheral blood cells, and cells incubated under circumstances that induce osteoclastic differentiation. We will develop osteoclastic cell lines, since these could make a major contribution to analysis of the regulation of osteoclastic function. We propose to exploit our access to osteoclastomas. These tumours provide an opportunity to identify the osteoblastic phenotype associated with osteoclastic stimulation. We will raise monoclonal antibodies to the osteoblastic cells in these tumors, and develop cell lines which will further enable characterization of this phenotype. We propose to use osteoclasts from these tumors, as the only practicable source of human osteoclasts, to test the responsiveness of human osteoclasts, particularly to cytokines and growth factors that show species specificity. The tumors also represent a bulk of osteoclasts otherwise unavailable in mammals, from which we propose to purify and characterize the enzymes that resorb bone, with a view to identification of characteristics that may be amenable to therapeutic intervention, and to the development of novel markers for the measurement of resorptive activity in vitro and in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR039623-03
Application #
3159807
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Project Start
1989-09-30
Project End
1992-08-31
Budget Start
1991-09-15
Budget End
1992-08-31
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of London
Department
Type
DUNS #
City
London
State
Country
United Kingdom
Zip Code
Fuller, K; Gallagher, A C; Chambers, T J (1991) Osteoclast resorption-stimulating activity is associated with the osteoblast cell surface and/or the extracellular matrix. Biochem Biophys Res Commun 181:67-73
Fuller, K; Chambers, T J; Gallagher, A C (1991) Heparin augments osteoclast resorption-stimulating activity in serum. J Cell Physiol 147:208-14